Profil bibliographique

Grzegorz S. Obara

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

8Publications signalées

271Citations signalées

0Affiliations récentes

Domaines associés

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsHead and Neck Cancer StudiesCAR-T cell therapy researchGlioma Diagnosis and Treatment

Publications récentes

Accès ouvert 2025 supplementary-materialsOpenAlex

Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jérôme Fayette, Lisa Licitra, Kevin J. Harrington, Robert I. Haddad et autres

0 citations

Accès ouvert 2025 otherOpenAlex

Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Lisa Licitra, Kevin J. Harrington, Robert I. Haddad, Lillian L. Siu et autres

0 citations

Accès ouvert 2025 articleOpenAlex

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jérôme Fayette, Lisa Licitra, Kevin J. Harrington, Robert I. Haddad et autres

26 citationsClinical Cancer Research

2024 conference-abstractOpenAlex

Phase 1 study (NCT04931823) of CPO100 (albumin bound docetaxel) in patients with advanced solid tumors.

Dale R. Shepard, Ed Kingsley, John D. Powderly, Patricia LoRusso et autres

1 citationJournal of Clinical Oncology

Accès ouvert 2024 articleOpenAlex

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness et autres

240 citationsThe Lancet Oncology

2022 conference-abstractOpenAlex

Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Grzegorz S. Obara, Jichao Sun, Deryk Loo, Gerry C. Bohac

3 citationsJournal of Clinical Oncology

Accès ouvert 2021 articleOpenAlex

926TiP Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)

Grzegorz S. Obara, Jichao Sun, Deryk Loo, Chet Bohac

2 citationsAnnals of Oncology

1996 articleOpenAlex

Aktualne propozycje modernizacji i budowy połączenia drogowego (Kraków-Myślenice) Lubień-Zakopane

Janusz T. Cieśliński, Tadeusz Kopta, Grzegorz S. Obara, Danuta Palonek

0 citations

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.